Back to search
FDAFDA · Food and drugs·Recall number Z-0780-2024

Model A710 Intellis Clinician Programmer Application, version 2.0.97

Published January 31, 2024 · Recall initiated: December 19, 2023

Summary

FDA records medical device Class II recall Z-0780-2024, published January 31, 2024 and initiated December 19, 2023. Recalling firm: Medtronic Neuromodulation; Status: Ongoing; Reported quantity: 1 tablet; Lot: UDI/DI 00763000520076, S/N: NPL1000519. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Medtronic has discovered an instance in which the Intellis A710 Clinician Programmer Application (CP App) could no longer establish a session with the Implantable Neurostimulator (INS) which resulted in the inability for the clinician to adjust stimulation parameters. In the event of this issue, the patient may receive inadequate or excessive therapy and experience non-optimal pain relief.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Medtronic Neuromodulation
Distributor
Germany
Lot
UDI/DI 00763000520076, S/N: NPL1000519
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Model A710 Intellis Clinician Programmer Application, version 2.0.97 recalled?

Yes. FDA published recall Z-0780-2024 on January 31, 2024. Reported hazard: Medtronic has discovered an instance in which the Intellis A710 Clinician Programmer Application (CP App) could no longer establish a session with the Implantable Neurostimulator (INS) which resulted in the inability for the clinician to adjust stimulation parameters. In the event of this issue, the patient may receive inadequate or excessive therapy and experience non-optimal pain relief.

What should I do if I have this product?

Voluntary: Firm initiated · Letter